Influence of SGLT2 inhibitors on plasma glycemic fluctuations and oxidative stress in patients with newly diagnosed type 2 diabetes mellitus

被引：0
|
作者：
Zhou, Peihua [1 ]
Ma, Jianhua [1 ]
Li, Fengfei [1 ]
机构：
[1] Nanjing First Hosp, Nanjing, Jiangsu, Peoples R China
来源：
DIABETES-METABOLISM RESEARCH AND REVIEWS | 2016年 / 32卷 / SUPP 2期
关键词：
SGLT2; inhibitors; dapagliflozin; T2DM; blood glycemic fluctuations; oxidative stress;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
384458
引用
收藏
页码：40 / 40
页数：1
相关论文
共 50 条
  • [31] The Potential Role of SGLT2 Inhibitors in the Treatment of Type 1 Diabetes Mellitus
    Fattah, Hadi
    Vallon, Volker
    DRUGS, 2018, 78 (07) : 717 - 726
  • [32] Clinical Outcomes in Patients with Type 2 Diabetes Newly Initiating SGLT2 or DPP4 Inhibitors
    Adimadhyam, Sruthi
    Isaman, Danielle
    Weckstein, Andrew
    Payne, Emma
    Yu, Edward
    Louder, Anthony
    Reynolds, Shannon L.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2019, 28 : 36 - 37
  • [33] Effect of Zinc Supplementation on Glycemic Control in Newly Diagnosed Patients With Type 2 Diabetes Mellitus
    Chhina, Gurpreet S.
    Chhabra, Ajay
    Luthra, Sumedh R.
    Khattar, Saloni
    Singh, Priyanka
    Luthra, Shivansh
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2024, 16 (09)
  • [34] SGLT2 Inhibitors for the Prevention of Kidney Failure in Patients with Type 2 Diabetes
    Pavlicek, Vojtech
    DIABETOLOGE, 2019, 15 (07): : 663 - 664
  • [35] Changes in Cardiovascular and Renal Biomarkers Associated with SGLT2 Inhibitors Treatment in Patients with Type 2 Diabetes Mellitus
    Peppa, Melpomeni
    Manta, Aspasia
    Mavroeidi, Ioanna
    Asimakopoulou, Athina
    Syrigos, Alexandros
    Nastos, Constantinos
    Pikoulis, Emmanouil
    Kollias, Anastasios
    PHARMACEUTICS, 2023, 15 (11)
  • [36] The Kidney Effects of the SGLT2 Inhibitors on the Japanese Type 2 Diabetes Mellitus Patients with Chronic Kidney Disease
    Kobayashi, Kazuo
    Toyoda, Masao
    Hatori, Nobuo
    Sakai, Hiroyuki
    Furuki, Takayuki
    Tamura, Kouichi
    Miyakawa, Masaaki
    DIABETES, 2019, 68
  • [37] SGLT2 inhibitors for patients with type 2 diabetes and CKD: a narrative review
    Thomas, Merlin C.
    Neuen, Brendon L.
    Twigg, Stephen M.
    Cooper, Mark E.
    Badve, Sunil, V
    ENDOCRINE CONNECTIONS, 2023, 12 (08)
  • [38] SGLT2 INHIBITORS AND KIDNEYS: MECHANISMS AND MAIN EFFECTS IN DIABETES MELLITUS PATIENTS
    Salukhov, Vladimir V.
    Khalimov, Yurii Sh
    Shustov, Sergey B.
    Popov, Sergey, I
    DIABETES MELLITUS, 2020, 23 (05): : 475 - 491
  • [39] SGLT2 inhibitors: the future for treatment of type 2 diabetes mellitus and other chronic diseases
    Christoph Wanner
    Nikolaus Marx
    Diabetologia, 2018, 61 : 2134 - 2139
  • [40] SGLT2 inhibitors: a promising new therapeutic option for treatment of type 2 diabetes mellitus
    Misra, Monika
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2013, 65 (03) : 317 - 327
12345